Imagine a pacemaker where a microscopic amount of uncured residue migrates into cardiac tissue, initiating a localised inflammatory cascade.
Or consider an implantable glucose sensor where electrolyte ingress through a hairline defect destabilises readings within hours. In medical electronics, even a single microvolt shift can impact diagnosis, and a material failure can alter patient outcomes.
Modern medical devices integrate dense microelectronics: miniaturised sensors, microfluidic pathways, power modules, RF telemetry, and increasingly, closed-loop diagnostic logic.
These components operate inside biological ecosystems defined by moisture, salts, enzymes, proteins, pH variability, and sterilisation temperatures exceeding 134°C.
Here’s the challenge.
Commodity encapsulants often release trace extractables, such as unreacted monomers, catalysts, or low-molecular-weight volatiles that are capable of provoking cytotoxic or sensitisation responses at parts-per-million levels.
This is where epoxy chemistry becomes mission-critical.
Biocompatible epoxy potting systems for medical electronics must simultaneously deliver dielectric insulation, moisture resistance, mechanical stability, sterilisation durability, and most importantly, biological safety.
At Kohesi Bond, we engineer epoxy potting for medical electronics grounded in molecular-level purity, toxicological transparency, and the reliability expectations of long-term implantable and diagnostic devices.
Our formulations are designed to perform their protective function without introducing biological risk.
A] What is Biocompatibility in Medical Devices?
1. Definition and Regulatory Standards
Biocompatibility, defined in ISO 10993-1:2018, refers to the ability of a material to perform its intended function in contact with the human body without causing harmful biological responses. In practice, it represents a multi-layered testing framework governed by:
- ISO 10993 series (cytotoxicity, sensitisation, irritation, systemic toxicity, hemocompatibility, genetic toxicity, implantation)
- USP Class VI protocols (systemic toxicity, intracutaneous reactivity, implantation tests)
Let’s quantify the expectations:
- ISO 10993-5 Cytotoxicity: >70% L929 fibroblast viability
- ISO 10993-10 Sensitisation: no delayed hypersensitivity response
- ISO 10993-11 Systemic Toxicity: no acute toxic response to material extracts
- USP Class VI: rigorous extraction at elevated temperatures to simulate worst-case leaching
These standards form the backbone of global regulatory acceptance, including FDA submissions.
2. Scope of Biocompatibility Testing
ISO 10993-1 requires testing based on:
- Anatomical contact category: surface, external communicating, implant
- Exposure duration: limited (<24 h), prolonged (1–30 days), permanent (>30 days)
For example:
- A wearable ECG patch: cytotoxicity + irritation + sensitisation
- An intravascular catheter: hemocompatibility under ISO 10993-4
- An implantable pressure sensor: systemic toxicity, implantation studies, and leachables analysis
Even materials with excellent mechanical properties may fail biocompatibility if extractable species breach toxicological thresholds. This is why recent FDA guidance emphasises chemical characterisation (ISO 10993-18) and toxicological risk assessment using TTC (Threshold of Toxicological Concern).
3. Relevance to Epoxy Potting Compounds
Potting materials rarely exist in complete biological isolation. Consider:
- A catheter connector where cured epoxy forms the outer barrier against saline
- A wearable patch where potted electronics sit millimetres from skin
- An implantable sensor housing where volatiles can migrate through polymer membranes
Here’s why this matters.
Even “indirect-contact” devices may expose patients to vapour-phase or permeated extractables.
Therefore, medical-grade epoxy for potting certified systems must be formulated from resin and hardener chemistries with proven toxicological profiles, which are often DGEBA/DGEF systems paired with cycloaliphatic amines or anhydrides for clean-cure networks.
4. Kohesi Bond’s Assurance
We do not treat ISO 10993 compliance as a checkbox.
Our medical-grade epoxies use raw materials with documented purity and supplier medical master files. Every batch undergoes strict characterisation, and biocompatibility is validated through GLP-accredited testing laboratories. This ensures reproducibility, traceability, and regulatory confidence.
B] Why Epoxy Potting is Used in Medical Devices
1. Overview of ASTM E595
Moisture ingress is the leading cause of electronic failure in medical systems. Blood saline exhibits ~1.5 S/m conductivity, which is enough to short unprotected traces instantly. Medical-grade epoxies provide:
- Dielectric strength: 15–25 kV/mm
- Water absorption: 0.1–0.5% (ASTM D570), often reduced to <0.2% through resin optimisation
These low-absorption networks minimise dielectric drift and resist ionic contamination. In addition, vibration damping from epoxy matrices (storage modulus 2–3 GPa at 25°C) protects solder joints, wire bonds, and microcomponents from fatigue
2. Sterilisation Compatibility
Sterilisation is one of the harshest stressors for polymers.
- EtO Gas (37–55°C): Requires low-plasticiser formulations with minimal gas uptake and fast desorption to meet ISO 10993-7 EtO residual limits.
- Gamma Irradiation (25–40 kGy): Aromatic epoxy networks exhibit superior radiation stability, maintaining ≥70% mechanical strength and low yellowing (ΔE <5).
Autoclave (121–134°C steam): Demands systems with Tg >150°C and high hydrolytic resistance — properties only achievable through high-functionality resins and robust crosslink density.
3. Chemical and Mechanical Stability
Medical environments expose materials to:
- Isopropyl alcohol
- Hydrogen peroxide
- Glutaraldehyde
- Peracetic acid
- Enzyme-rich bodily fluids
High-performance epoxies maintain:
- <1% weight change after prolonged chemical exposure
- Dimensional change <0.5% after months in 37°C saline
- Adhesion >1,500 psi on metals and engineering plastics.
4. Kohesi Bond’s Engineering Focus
Our medical-grade epoxies inherit reliability principles from our aerospace-grade formulations. Each system undergoes internal validation across:
- Autoclave cycling
- Gamma irradiation
- Chemical immersion
- Thermal cycling
- Electrical insulation stability
We engineer with the assumption that failure is unacceptable.
Secure Reliable Potting for Your Medical Devices
Ensure safety and compliance with Kohesi Bond’s biocompatible epoxies—get expert advice today.
C] Selecting Biocompatible Epoxies: Key Properties to Consider
1. Certification and Compliance
Regulatory confidence begins with verified biological testing:
- ISO 10993-5 (Cytotoxicity)
- ISO 10993-10 (Sensitisation/Irritation)
- ISO 10993-11 (Systemic Toxicity)
Devices with blood contact require ISO 10993-4 hemocompatibility. Chemical characterisation per ISO 10993-18 identifies extractables via GC-MS, LC-MS/MS, and ICP-MS, supported by toxicological thresholds under ISO 10993-17.
2. Thermal and Processing Performance
Medical electronics such as RF devices, implantable stimulators, and catheter ablation circuits often generate localised heat. Epoxy potting for catheter electronics requires materials that maintain:
- Tg ≥ (max service temp + 30°C)
- CTE: 40–80 ppm/°C to align with FR-4 (~16 ppm/°C) or titanium (~9 ppm/°C)
During the curing process, the chemical reaction between the resin and hardener releases energy as heat.
For sensitive medical microelectronics, it is vital to calculate this controlled exotherm using the following relationship: Q = ΔH × ρ × V
Understanding the equation:
Q = Total amount of heat energy released (in joules)
ΔH = Enthalpy of reaction (typically 80–110 kJ/mol), representing the chemical energy potential of the epoxy system
ρ = Density of the potting compound
V = Total volume of material used
Why this matters for medical devices:
This relationship shows that as the volume (V) of the potting compound increases, the total heat generated (Q) rises proportionally.
If the exotherm is too high, it can damage sensitive components such as CMOS sensors or thin-film circuits.
Kohesi Bond engineers low-exotherm systems to ensure that even in deep pours, peak temperature rise remains safe for surrounding electronics.
3. Dimensional and Mechanical Stability
Conventional epoxies shrink 2% to 5% during cure; medical-grade systems limit shrinkage to ≤1.5% using fillers and tailored resin architectures. Long-term immersion stability demands <0.5% dimensional drift.
Mechanical metrics:
- Shore D: 75–85
- Flexural modulus: 2.5–4.0 GPa
- Lap shear strength: >1,500 psi
4. Ease of Processing
Manufacturability depends on:
- Viscosity: 500–5,000 cP
- Pot life: 30–120 minutes for two-part systems
- One-part stability: 6–12 months RT
- Cure schedules: room-temperature or 80–150°C thermal cure
Flow behaviour and air-release properties determine void-free encapsulation, which is essential for microelectronics.
5. Kohesi Bond’s Expertise
As a leading adhesive manufacturer in India, our formulations are guided by decades of formulation experience that balance conflicting needs: biocompatibility, sterilisation durability, low viscosity, optical clarity, thermal conductivity, and electrical insulation.
D] Kohesi Bond’s Biocompatible Epoxy Systems — Engineered for Medical Reliability
1. Tested and Certified Grades
Let’s be absolutely clear: in medical devices, the encapsulant is not a passive passenger.
It’s an active reliability component.
That’s why Kohesi Bond maintains a portfolio of formulations explicitly engineered and validated for medical environments, each undergoing rigorous ISO 10993 biological evaluations.
- Two-Part Room-Temperature Cure Systems
These systems provide controlled pot life, typically 30 to 90 minutes, achieving full polymerisation within 24 to 72 hours at 23°C.
Their low exotherm behaviour and balanced viscosity profiles make them ideal for precision sensor encapsulation, catheter connectors, and diagnostic modules where dimensional stability and void-free wet-out are non-negotiable.
- One-Part Heat-Cure Epoxies
Designed for automated production lines, these pre-catalysed materials remain stable at room temperature but activate at 80°C to 150°C. The benefit is clear: zero mix-ratio deviation, consistent dispense characteristics, and high repeatability for implantable electronics, wearable monitors, and high-volume surface-mount assemblies.
- Optically Clear Grades
UV-transparent systems engineered to retain >90% transmission across the visible spectrum even after sterilisation. These formulations are mission-critical for endoscopic optics, photodiodes, optical biosensors, and other imaging-driven modalities where clarity is synonymous with diagnostic accuracy.
- Thermally Conductive Variants
Filled epoxy systems achieve 1.0 W/m·K to 2.5 W/m·K thermal conductivity without compromising dielectric strength or biocompatibility.
These are increasingly leveraged in RF ablation tools, high-power LEDs, battery-powered implantable systems, and energy-delivery devices where thermal load cannot be ignored. Every Kohesi Bond formulation in this portfolio offers epoxy potting for medical devices that protects patient safety and circuit integrity.
Every formulation in this portfolio undergoes baseline testing under ISO 10993-5 (cytotoxicity), 10993-10 (sensitisation/irritation), and 10993-11 (systemic toxicity) through accredited laboratories, ensuring that biological safety is engineered, verified, and documented.
2. Product Advantages
- Sterilisation Resistance
Now, here’s where the science is unforgiving.
Sterilisation cycles impose extreme thermal, oxidative, and hydrolytic stresses. Kohesi Bond systems demonstrate validated performance through:
- 100+ autoclave cycles at 121°C–134°C
- Gamma exposure up to 25–40 kGy with minimal mechanical degradation
- Repeated exposure to chemical sterilisers, including hydrogen peroxide, glutaraldehyde, and peracetic acid
The implication is simple: these networks are engineered to maintain modulus, adhesion, and dimensional stability even after the full sterilisation burden typical of reusable or critical-care devices.
- Moisture and Chemical Resistance
What the data consistently shows is that long-term immersion in biological and clinical fluids is a brutal test for polymer networks. Kohesi Bond systems exhibit:
- Water absorption <0.2% after 24-hour immersion (ASTM D570)
- High resistance to saline, 70% isopropyl alcohol, enzymatic fluids, and disinfectants
- <1% weight change after extended chemical exposure
- >95% retention of adhesion strength on stainless steel and polymer substrates
This level of resistance directly translates into better electrical stability, lower leak currents, and reduced risk of moisture-driven delamination.
- High Mechanical Strength
Every percentage point of mechanical property retention matters when devices undergo vibration, flexion, or repeated sterilisation cycles. Kohesi Bond systems typically achieve:
- Shore D hardness of 75–85
- Flexural modulus of 2.5–4.0 GPa
- Lap shear strength >1,500 psi on stainless steel
- Stable performance under thermal cycling from –40°C to +125°C
These parameters are essential for structural potting applications, catheter electronics, and embedded systems subjected to physiological motion or mechanical shock.
- Thermal Conductivity With Electrical Insulation
Thermal dissipation and electrical insulation rarely coexist gracefully, and yet in medical electronics, they must. Advanced filled formulations deliver:
- 1.0–2.5 W/m·K thermal conductivity
- >10¹³ Ω·cm volume resistivity
This combination enables efficient heat spreading in RF ablation tools, implantable stimulators, battery systems, and compact imaging modules without compromising patient safety or circuit integrity.
- Low Exotherm Curing for Sensitive Electronics
During cure, an exotherm is not just a thermal nuisance; it can permanently alter MEMS responses, shift calibration points, or damage polymer housings. Kohesi Bond’s low-exotherm systems restrict peak temperature rise to:
- <80°C for a 100 g mass
This protects CMOS sensors, fine-pitch interconnects, flexible substrates, and polymer-based housings during encapsulation.
- Low Shrinkage for Dimensional Precision
Volumetric cure shrinkage is typically <1.8%, achieved through optimised resin architecture and filler loading.
Why does this matter?
In devices with optical alignment, microfluidic channels, or strain-sensitive components, even 1% shrinkage can shift calibration or seal integrity beyond acceptable limits.
- Fast Curing Options for High Throughput
For manufacturers balancing throughput and precision, Kohesi Bond offers:
- UV-activated systems reaching handling strength in 5 to 10 minutes under 1–2 W/cm² UV intensity
- Accelerated thermal cures reaching full polymerisation within 2 to 4 hours
These profiles support lean manufacturing environments, automated assembly, and rapid prototyping workflows.
- Optical Clarity for Imaging-Based Devices
For optical systems, clarity is not just cosmetic; it’s also functional.
Kohesi Bond’s optical-grade materials deliver:
- >90% transmission (400–700 nm)
- >70% transmission (700–1100 nm)
- Minimal yellowing (ΔE < 3) even after 25–40 kGy gamma irradiation
This ensures stability for endoscopes, biosensors, optical detectors, photodiodes, and minimally invasive imaging tools.
3. Application Areas
Kohesi Bond formulations support a wide range of medical technologies, including:
- Sensor encapsulation in catheters, implantable monitors, and neurostimulation leads
- Moisture-barrier protection for catheter connectors and wearable devices
- Potting for implantable electronics requiring long-term chemical and thermal stability
- Encapsulation in surgical instruments undergoing repeated sterilisation
- Structural bonding in diagnostic and laboratory equipment
- Optical and microfluidic modules demanding clarity and low shrinkage
The common denominator across these applications is the need for high-purity, biologically safe, and mechanically robust encapsulation materials.
4. Collaborative Development Support
This is exactly where Kohesi Bond distinguishes itself. Beyond supplying materials, our technical team partners with OEMs across the entire product lifecycle:
- Material selection consulting matched to device architecture and sterilisation method
- Custom formulation development for unique electrical, optical, or thermal constraints
- Regulatory documentation support aligned with ISO 10993, USP Class VI, and FDA expectations
- Process optimisation for dispensing, curing, and high-volume manufacturing
- Failure analysis and root-cause investigations when assembly or field issues arise
In practice, this means manufacturers gain not just an epoxy but an engineering partner committed to device reliability from concept to commercialisation.
E] Conclusion
In medical devices, every material is a risk, unless engineered otherwise.
Biocompatible epoxy potting is not merely physical protection; it is the interface between advanced electronics and the human body.
The narrative is clear:
- Biological environments are hostile.
- Sterilisation cycles are unforgiving.
- Regulatory requirements are rigorous.
- Device miniaturisation amplifies consequences of material failure.
This complexity explains why medical device manufacturers increasingly rely on scientifically engineered, rigorously tested epoxy systems rather than commodity formulations.
At Kohesi Bond, our biocompatible epoxy solutions pair high-fidelity protection with certified biological safety that is engineered for applications where failure is simply not an option.
Protecting Patient Safety Starts with the Right Epoxy
Discover how Kohesi Bond’s solutions deliver unmatched reliability for your devices.
FAQs
Biocompatible epoxy potting refers to encapsulation materials engineered to protect medical electronics without eliciting adverse biological responses when used in direct or indirect patient-contact applications.
These systems undergo comprehensive evaluations under ISO 10993 (cytotoxicity, sensitisation, irritation, and systemic toxicity) and, when applicable, USP Class VI testing.
Here’s why this matters: unlike industrial-grade resins, medical-grade epoxies are formulated using high-purity raw materials, controlled catalysts, and chemistries with well-characterised toxicological profiles.
Selecting the correct system is not a single-parameter decision; it is a structured engineering process. What the data consistently shows is that five factors dictate suitability:
- Device Contact Category (ISO 10993-1): Surface vs. external communicating vs. implant determines the required biological endpoints.
- Sterilisation Method: Autoclave, gamma, EtO, or hydrogen peroxide plasma imposes fundamentally different thermal and chemical stresses.
- Environmental Load: Exposure to moisture, saline, enzymes, disinfectants, temperature cycling, and mechanical vibration.
- Mechanical/Thermal Requirements: Shrinkage limits, CTE compatibility, Tg margin over operating temperature, and modulus behaviour at 37°C.
- Manufacturing Constraints: Viscosity for dispensing, pot life for assembly throughput, cure kinetics, and void control during potting.
Here’s the practical takeaway: request ISO 10993 reports from GLP labs, sterilisation-resistance validation (e.g., gamma retention data, EtO aeration profiles), and chemical compatibility testing in relevant clinical simulants.
The difference is predominantly in processing architecture, not performance:
- One-Part Epoxies: Pre-mixed and stable at room temperature; require heat activation (typically 80°C to 150°C). Ideal for automated, high-volume production where mix-ratio precision and dispensing consistency are critical.
- Two-Part Epoxies: Resin and hardener mixed immediately before application; cure at room temperature or with mild heat. Essential for temperature-sensitive components, large potting volumes requiring low-exotherm behaviour, and applications needing extended working time.
Both can be fully compliant with ISO 10993 and USP Class VI when engineered accordingly. The choice depends not on biology, but on assembly workflow, component sensitivity, and throughput requirements.
There is no universal “best” option. The optimal epoxy bonding adhesive is defined by the sterilisation method your device must withstand.
- Autoclave (121–134°C steam): Requires high-Tg systems (Tg ≥150°C) and strong hydrolysis resistance. Aromatic amine-cured epoxies generally outperform aliphatic systems.
- Gamma Radiation (25–40 kGy): Requires epoxies with radiation-stable aromatic backbones that maintain ≥70% mechanical property retention and low yellowing (ΔE < 5).
- Ethylene Oxide (EtO): Demands low-plasticiser formulations and minimal volatile content to reduce gas absorption and ensure fast desorption to meet ISO 10993-7 residue limits.
- Hydrogen Peroxide Plasma: Favours high crosslink density to prevent oxidative softening.
The implication is simple: match the polymer network to the sterilisation physics, not the other way around.
Multiple Kohesi Bond epoxy systems undergo independent, GLP-certified testing to achieve compliance across these frameworks. Certification typically includes:
- USP Class VI:
Systemic injection toxicity, intracutaneous reactivity, and implantation testing under aggressive extraction conditions. - ISO 10993 Core Tests:
- Cytotoxicity (10993-5)
- Sensitisation and Irritation (10993-10)
- Systemic Toxicity (10993-11)
Additional ISO endpoints, such as hemocompatibility (10993-4) or implantation studies (10993-6), are selected based on device contact category.
Documentation packages include validated test reports, chemical characterisation, and certificates of analysis that support regulatory submissions to the FDA, EU MDR, or other global authorities.
Utsav Shah is a 34-year-old entrepreneur with a passion for scientific discovery. Utsav’s journey began with a deep dive into materials science, earning degrees from USC and the Institute of Chemical Technology. He’s the visionary founder of Kohesi Bond, a top-rated adhesive manufacturer, and Cenerge Engineering Solutions, a leader in heat exchangers and cryogenic pumps. With over a decade of experience, Utsav consults across various industries, ensuring they have the perfect adhesive solution for their needs. Connect with him on LinkedIn!
